Catalyst Pharmaceuticals Announces Appointment of Richard J. Daly and Donald A. Denkhaus to its Board of Directors

Catalyst Pharmaceuticals Announces Appointment of Richard J. Daly and

Donald A. Denkhaus to its Board of Directors

CORAL GABLES, Fla., Feb 19, 2015 Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused

on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Richard J. Daly and Donald A. Denkhaus to the Company s Board of Directors.

Catalyst is pleased to welcome such exceptional and successful pharmaceutical business leaders to its board, adding additional financial, operational

and commercial expertise as we transform from a clinical stage company to a commercial operation, said Patrick J. McEnany, Chairman and CEO of Catalyst.

Mr. Daly has over 20 years of

commercial pharmaceutical experience working in positions of progressive responsibility in sales, marketing and operations. Recently, Mr. Daly was the President of U.S. Diabetes for the joint alliance between Bristol-Myers Squibb and

AstraZeneca. In the past Mr. Daly was a founding partner and board member of SagePath Partners LLC, a commercial outsourcing provider to the pharmaceutical industry. During his recent tenure at Takeda Pharmaceuticals he served as Executive Vice

President with P&L responsibility for businesses across the U.S., Canada, and Central/South America. Earlier in his career, he served in the sales organizations at Merrell-Dow Pharmaceuticals (now part of Sanofi) and TAP Pharmaceuticals

(formerly a division of Abbott Labs) in sales, marketing, operations and senior leadership positions at TAP and Takeda. Mr. Daly holds a BS in Microbiology from The University of Notre Dame and an MBA from Northwestern University s Kellogg

School of Management.

Mr. Denkhaus is a senior financial executive and CPA with forty years of broad-based business experience. He was a member of the Board of Directors of

Noven Pharmaceuticals, Inc., a specialty pharmaceutical company focused on woman s health and psychiatry from 2004 until it was sold in August 2009. He served as chairman of Noven s Audit Committee and meets the SEC requirements as an

audit committee financial expert . Mr. Denkhaus was with Arthur Andersen, global professional services firm, from 1970 to 2002, where he spent 22 years as an audit partner, including serving several publicly-held South Florida

pharmaceutical companies. From 2010 through 2013 he was Chairman of Nuovo Biologics, LLC, a privately held company that is developing an antiviral drug, initially for animal use. Additionally, Mr. Denkhaus is currently chairman and chief

financial officer of a privately-held company that provides dubbing and subtitling to the television industry. He received a Masters of Business Administration degree with a major in finance from the University of Maryland and a Bachelors of

Business Administration with a major in accounting from Kent State University.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating

diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst s lead candidate, Firdapse for the treatment of LEMS, recently completed testing in a global, multi-center, pivotal Phase 3

trial resulting in positive top-line data. Firdapse for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Firdapse is the first and only European approved drug for

symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions

associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette Syndrome. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal

product designation for the treatment of West Syndrome by the European Commission.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause

Catalyst s actual results in future periods to differ materially from forecasted results. A number of factors, including whether the receipt of breakthrough therapy designation for Firdapse will expedite the development and review of

Firdapse by the FDA or the likelihood that the product will be found to be safe and effective, whether an NDA for Firdapse will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether Catalyst

will be the first company to receive approval for amifampridine (3,4-DAP), giving it 7-year marketing exclusivity for its product, whether CPP-115 will be determined to be safe for humans, whether CPP-115 will be determined to be effective for the

treatment of infantile spasm, post-traumatic stress disorder, Tourette Syndrome or any other indications, whether any of Catalyst s product candidates will ever be approved for commercialization or successfully commercialized, and those other

factors described in Catalyst s Annual Report on Form 10-K for the fiscal year 2013 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst s filings with the SEC

are available from the SEC, may be found on Catalyst s website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Matt Middleman, M.D.